|
1
|
Smith M and Visootsak J: Noninvasive
screening tools for Down syndrome: A review. Int J Womens Health.
5:125–131. 2013.PubMed/NCBI
|
|
2
|
Duan Y, Li Y and Xue Q: Serological
prenatal screening and diagnosis for Down syndrome. Clin Exp Obstet
Gynecol. 41:572–574. 2014.PubMed/NCBI
|
|
3
|
Huang J, Chen Y and Pong RW: Factors
influencing prenatal screening for Down's syndrome: Evidence from
Zhejiang (China). Asia Pac J Public Health. 27:NP1288–NP1297. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sirichotiyakul S, Luewan S, Sekararith R
and Tongsong T: False positive rate of serum markers for Down
syndrome screening: Does transportation have any effect? J Med
Assoc Thai. 95:152–155. 2012.PubMed/NCBI
|
|
5
|
Wald NJ, Barnes IM, Birger R and Huttly W:
Effect on Down syndrome screening performance of adjusting for
marker levels in a previous pregnancy. Prenat Diagn. 26:539–544.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Androutsopoulos G, Gkogkos P and Decavalas
G: Mid-trimester maternal serum HCG and alpha fetal protein levels:
Clinical significance and prediction of adverse pregnancy outcome.
Int J Endocrinol Metab. 11:102–106. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Extermann P, Bischof P, Marguerat P and
Mermillod B: Second-trimester maternal serum screening for Down's
syndrome: Free beta-human chorionic gonadotrophin (HCG) and
alpha-fetoprotein, with or without unconjugated oestriol, compared
with total HCG, alpha-fetoprotein and unconjugated oestriol. Hum
Reprod. 13:220–223. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sayin NC, Canda MT, Ahmet N, Arda S, Süt N
and Varol FG: The association of triple-marker test results with
adverse pregnancy outcomes in low-risk pregnancies with healthy
newborns. Arch Gynecol Obstet. 277:47–53. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shaw SW, Lin SY, Lin CH, Su YN, Cheng PJ,
Lee CN and Chen CP: Second-trimester maternal serum quadruple test
for Down syndrome screening: A Taiwanese population-based study.
Taiwan J Obstet Gynecol. 49:30–34. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nix B, Wright D and Baker A: The impact of
bias in MoM values on patient risk and screening performance for
Down syndrome. Prenat Diagn. 27:840–845. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bishop J, Dunstan FD, Nix BJ and Reynolds
TM: The effects of gestation dating on the calculation of patient
specific risks in Down's syndrome screening. Ann Clin Biochem.
32:464–477. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li Y, Zhang X, Sun Y, Hong D, Wang Y, Xu Z
and Jiang T: Combined detection of α-fetoprotein and free β-human
chorionic gonadotropin in screening for trisomy 21 and management
of cases in the moderate risk value range. Mol Clin Oncol.
7:623–628. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Parikh AM, Park AM and Sumfest J:
Cumulative summation (CUSUM) charts in the monitoring of
hypospadias outcomes: A tool for quality improvement initiative. J
Pediatr Urol. 10:306–311. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Leandro G, Rolando N, Gallus G, Rolles K
and Burroughs AK: Monitoring surgical and medical outcomes: The
Bernoulli cumulative SUM chart. A novel application to assess
clinical interventions. Postgrad Med J. 81:647–652. 2005.
View Article : Google Scholar : PubMed/NCBI
|
